ReviewFrontiers in psychiatry2024
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.
Review in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- AI-powered cognitive remediation for schizophrenia: a psychologist's lens on evidence and scalability in India.Frontiers in psychology · 2026Pooled it
- Cognitive rehabilitation in schizophrenia research: a bibliometric and visualization analysis.Frontiers in psychiatry · 2024Pooled it
- Efficacy Analysis of Evidence-Based Nursing Combined With Computer-Assisted Cognitive Correction Therapy on Cognitive Function and Quality of Life in Patients With Schizophrenia.Actas espanolas de psiquiatria · 2026Article
- Real-world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- Overcoming Patient Access Barriers in Complex Conditions: Lessons from Schizophrenia for Broader Healthcare Applications.Journal of market access & health policy · 2026Article
- Abnormal plasma oxidative stress markers in first-episode schizophrenia and associations with clinical symptoms and cognitive function.Schizophrenia (Heidelberg, Germany) · 2026Article
- The Lived Experience of Cognitive Impairment Associated With Schizophrenia: A Conceptual Model.Schizophrenia bulletin open · 2026Article
- Improving care for cognitive impairment in schizophrenia: current perspectives and opportunities in Portugal (a consensus development conference).Frontiers in psychiatry · 2026Article
- Preliminary Data Regarding the Alleviating Effects of Haloperidol and Risperidone on the Short-Term Memory and Associative Learning in a Zebrafish Model of Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Cognitive impairment and its influencing factors in patients with stable schizophrenia on regular medication: a real-world clinical study.BMC psychiatry · 2025Article
- Reduced Cerebellar Volumes Associate with P300 Amplitude Attenuation in Children with Clinical High Risk for Psychosis and Early Onset Psychosis.Cerebellum (London, England) · 2025Article
- Virtual reality interventions for cognitive remediation in severe mental illness.Neuroscience applied · 2025Article
- Article
- Biomarkers in schizophrenia - past, present and future.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A considerable proportion of patients with schizophrenia perform below population norms on standardized neuropsychological tests, and the performance of those performing within normal range is lower than predicted based on parental education. Cognitive impairment predates the onset of psychosis, is observed during symptom remission and in non-affected first-degree relatives of patients. At the present time, cognitive deficits are regarded as key features of schizophrenia, important determinants of poor psychosocial outcome and targets for both pharmacological and non-pharmacological treatment strategies. A group of eight key opinion leaders reviewed and discussed latest advances in scientific research and current good clinical practices on assessment, management, and treatment of CIAS. In the present paper they summarize the current evidence, identify main gaps between current knowledge and mental health services clinical practice, and provide practical recommendations to reduce the gap.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.